Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)

Source :: Plus Company Updates. December 17, 2019
Publication Year :: 2019
Abstract: Chesterfield, MO: Avadel Pharmaceuticals has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Subjects :: United States. Food and Drug Administration
Cystine
Parenting
Newborn infants -- Food and nutrition
Cysteine
Drug approval
Thiols -- Intellectual property
Nutrition
Gamma hydroxybutyrate
Trademarks
Backup software
Narcolepsy
General interest
News, opinion and commentary

Tools